Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab added to neoadjuvant CROSS chemoradiotherapy and adjuvant durvalumab with or without tremelimumab in locally advanced esophageal adenocarcinoma
2018-003048-22Phase 2Terminated
- Sponsor
- University of Cologne
- Start
- Apr 2019
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of durvalumab and tremelimumab in esophageal adenocarcinoma (EAC) (3 arms), sponsored by University of Cologne. Primary endpoints: Pathological complete response rate and Progression-free survival. Started Apr 2019; status: terminated.
02
Drugs
durvalumabtremelimumab
03
Conditions
esophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on 2018-003048-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003048-22.